{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:43:43Z","timestamp":1791150223818,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jtho.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T12:19:30Z","timestamp":1543839570000},"page":"672-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib"],"prefix":"10.1016","volume":"14","author":[{"given":"Akihiko","family":"Gemma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Houzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.11.022_bib1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","article-title":"The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics","volume":"11","author":"Cheng","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib2","series-title":"Projected Cancer Statistics","year":"2017"},{"key":"10.1016\/j.jtho.2018.11.022_bib3","series-title":"Cancer Facts & Figures","year":"2018"},{"key":"10.1016\/j.jtho.2018.11.022_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrclinonc.2009.62","article-title":"Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC","volume":"6","author":"Linardou","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non\u2013small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non\u2013small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2018.11.022_bib8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ejca.2012.02.001","article-title":"ALK translocation and crizotinib in non\u2013small cell lung cancer: an evolving paradigm in oncology drug development","volume":"48","author":"Scagliotti","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2018.11.022_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib10","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/cncr.28604","article-title":"Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study","volume":"120","author":"Serizawa","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2018.11.022_bib11","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.11.022_bib12","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.11.022_bib13","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0000000000000318","article-title":"Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non\u2013small-cell lung cancer","volume":"9","author":"Blackhall","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib14","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.11.022_bib15","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib with chemotherapy: results from PROFILE 1014","volume":"36","author":"Solomon","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","article-title":"Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas","volume":"39","author":"Shah","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtho.2018.11.022_bib17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/JTO.0000000000000577","article-title":"Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review","volume":"10","author":"Cr\u00e9quit","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib18","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.cllc.2017.10.008","article-title":"Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature","volume":"19","author":"Pellegrino","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2018.11.022_bib19","doi-asserted-by":"crossref","first-page":"22137","DOI":"10.18632\/oncotarget.25154","article-title":"Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non\u2013small cell lung cancer","volume":"9","author":"Costa","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.11.022_bib21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cllc.2017.03.004","article-title":"Interstitial lung disease associated with crizotinib in patients with advanced non\u2013small cell lung cancer: independent review of four PROFILE trials","volume":"18","author":"Yoneda","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2018.11.022_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","article-title":"Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non\u2013small cell lung cancer treated with gefitinib","volume":"45","author":"Takano","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.11.022_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00130404-200509000-00010","article-title":"Interstitial lung disease in Japanese patients with non\u2013small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group","volume":"11","author":"Hotta","year":"2005","journal-title":"Cancer J"},{"key":"10.1016\/j.jtho.2018.11.022_bib24","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non\u2013small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib25","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2018.11.022_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1743-7563.2007.00090.x","article-title":"Gefitinib in advanced non\u2013small cell lung cancer: clinical experience in patients of Asian origin","volume":"3","author":"Armour","year":"2007","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib27","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non\u2013small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2018.11.022_bib28","doi-asserted-by":"crossref","first-page":"531302","DOI":"10.1155\/2011\/531302","article-title":"Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders","volume":"2011","author":"Kaarteenaho","year":"2011","journal-title":"Pulm Med"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2018.11.022_bib29","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","article-title":"Interstitial lung disease associated with drug therapy","volume":"91","author":"Camus","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.11.022_bib30","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1097\/JTO.0b013e318293dfc1","article-title":"Successful crizotinib retreatment after crizotinib-induced interstitial lung disease","volume":"8","author":"Yanagisawa","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib31","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/jjco\/hyu074","article-title":"Successful\u00a0crizotinib rechallenge after crizotinib-induced interstitial lung disease","volume":"44","author":"Tachihara","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1248\/yakushi.17-00194","article-title":"Analysis of Time-to-onset of interstitial lung disease after the administration of small molecule molecularly-targeted drugs","volume":"138","author":"Komada","year":"2018","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jtho.2018.11.022_bib33","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.11.022_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1272\/jnms.76.4","article-title":"Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents","volume":"76","author":"Gemma","year":"2009","journal-title":"J\u00a0Nippon Med Sch"},{"key":"10.1016\/j.jtho.2018.11.022_bib35","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","article-title":"Postmarketing surveillance\u00a0study of erlotinib in Japanese patients with\u00a0non\u2013small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)","volume":"7","author":"Nakagawa","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.11.022_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.resinv.2018.03.002","article-title":"Anticancer drug treatment for advanced lung cancer with interstitial lung disease","volume":"56","author":"Otsubo","year":"2018","journal-title":"Respir Investig"},{"key":"10.1016\/j.jtho.2018.11.022_bib37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for\u00a0the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418335007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418335007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:38:13Z","timestamp":1761561493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418335007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1556086418335007"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.11.022","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}